clinical trial · NCT04551911
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
COVID-19CoronavirusSARS-CoV2 InfectionRayaldeePlacebo
brief summary
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
started
Nov 2, 2020
primary completion
Oct 8, 2021
completion
Oct 8, 2021
last updated
May 28, 2024
official title
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol